Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BRTX
$0.2695
$
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Next Earnings
2026-02-25
Beta
0.236
Average Volume
Market Cap
Last Dividend
CIK
0001505497
ISIN
US0906556065
CUSIP
090655606
CEO
Lance Alstodt
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
11
IPO Date
2012-12-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs | MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.” | GlobeNewsWire | 2026-02-24 08:30:00 |
| BioRestorative Announces Closing of $5.0 Million Public Offering | MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.35 per share, are immediately exercisable and will expire five years from the date of issuance. | GlobeNewsWire | 2026-02-13 20:30:00 |
| BioRestorative Announces Pricing of $5.0 Million Public Offering | MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the pricing of a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $0.35 per share and will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about February 13, 2026, subject to the satisfaction of customary closing conditions. | GlobeNewsWire | 2026-02-11 22:30:00 |
| BioRestorative Announces Positive Outcome from Type B Meeting with FDA | MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today provided an update following the positive feedback received from the FDA regarding a potential expedited Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic lumbar disc disease (“cLDD”), based on a Type B meeting requested by the Company. | GlobeNewsWire | 2026-02-11 07:30:00 |
| BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease | Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placebo Prospective, randomized, double-blind, sham-controlled single-disc study - gold-standard clinical design Enrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing MELVILLE, N. | Globe News Wire | 2026-02-10 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13G | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-17 | 2026-02-13 | View Filing |
| SC 13G | 2026-02-13 | 2026-02-13 | View Filing |
| 424B4 | 2026-02-13 | 2026-02-13 | View Filing |
| EFFECT | 2026-02-11 | 2026-02-12 | View Filing |
| S-1/A | 2026-02-10 | 2026-02-10 | View Filing |
| S-1 | 2026-02-09 | 2026-02-09 | View Filing |
| SC 13G/A | 2025-12-19 | 2025-12-19 | View Filing |
| 424B3 | 2025-12-12 | 2025-12-12 | View Filing |
| EFFECT | 2025-12-10 | 2025-12-11 | View Filing |
| S-8 | 2025-11-18 | 2025-11-18 | View Filing |
| S-1 | 2025-11-18 | 2025-11-18 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-10-20 | 2025-10-20 | View Filing |
| 4 | 2025-10-20 | 2025-10-20 | View Filing |
| D | 2025-10-09 | 2025-10-09 | View Filing |
| 8-K | 2025-10-08 | 2025-10-08 | View Filing |
| 424B5 | 2025-10-08 | 2025-10-08 | View Filing |
| 424B5 | 2025-10-06 | 2025-10-06 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| DEF 14A | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-04-21 | 2025-04-21 | View Filing |
| 10-K | 2025-03-28 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| SC 13G/A | 2025-02-28 | 2025-02-28 | View Filing |
| SC 13D/A | 2025-02-19 | 2025-02-19 | View Filing |
| SC 13D/A | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| SC 13G/A | 2025-02-19 | 2025-02-19 | View Filing |
| SC 13G/A | 2025-02-10 | 2025-02-10 | View Filing |
| 8-K | 2025-02-10 | 2025-02-10 | View Filing |
| SC 13G/A | 2024-12-05 | 2024-12-05 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| S-8 | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-07 | 2024-11-06 | View Filing |
| 8-K | 2024-11-06 | 2024-11-06 | View Filing |
| 424B5 | 2024-11-06 | 2024-11-06 | View Filing |
| 10-K/A | 2024-11-06 | 2024-11-06 | View Filing |
| 4 | 2024-11-05 | 2024-11-05 | View Filing |
| 8-K | 2024-09-23 | 2024-09-23 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| DEF 14A | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| SC 13G | 2024-06-21 | 2024-06-21 | View Filing |
| 10-Q | 2024-06-11 | 2024-06-11 | View Filing |
| 10-K/A | 2024-06-11 | 2024-06-11 | View Filing |
| 8-K | 2024-05-24 | 2024-05-24 | View Filing |
| 8-K | 2024-05-24 | 2024-05-24 | View Filing |
| NT 10-Q | 2024-05-16 | 2024-05-16 | View Filing |
| 424B3 | 2024-04-19 | 2024-04-19 | View Filing |
| EFFECT | 2024-04-19 | 2024-04-19 | View Filing |
| S-1/A | 2024-04-12 | 2024-04-12 | View Filing |
| 4 | 2024-04-10 | 2024-04-10 | View Filing |
| S-1 | 2024-04-03 | 2024-04-03 | View Filing |
| 10-K | 2024-04-01 | 2024-03-29 | View Filing |
| 4 | 2024-03-20 | 2024-03-20 | View Filing |
| 4 | 2024-03-20 | 2024-03-20 | View Filing |
| 8-K | 2024-03-12 | 2024-03-12 | View Filing |
| SC 13D/A | 2024-03-06 | 2024-03-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Mean Reversion Strategy | 53.54% | 1.01 | 380 | 0.04 | 0.1 | 64.33 |
| Williams PercentR Strategy | 50.79% | 0.99 | 268 | 0.04 | 0.09 | 61.58 |
| Market Cycle | 38.17% | 1.01 | 282 | 0.03 | 0.07 | 48.96 |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |